As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing

Phase I study in Lenexa, KS, of novel vaccine targeting TB virulence and latency

24-Aug-2012 - Aeras and the Infectious Disease Research Institute (IDRI) announced the start of the first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 + GLA-SE. The Phase I clinical trial will assess the safety, tolerability and immunogenicity of the vaccine candidate in 60 healthy adult ...

Aeras awarded €11.7 million ($16 million) grant from Dutch government

16-Nov-2010 - The Aeras Global TB Vaccine Foundation announced that the Netherlands Ministry of Foreign Affairs has renewed its funding to Aeras with a pledge of an additional €11.7 million over four years (2011-2014) to further its efforts to develop new vaccines to help combat the global epidemic of ...

Aeras, Crucell and SATVI Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa

11-Apr-2008 - Crucell N.V., the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative (SATVI) presented a progress update and immunology data from a Phase I Ad35 tuberculosis vaccine study at the biennial "Tuberculosis Vaccines for the World" conference. The study, conducted ...

Vaccine formulated with Intercells adjuvant IC31 part of a broader collaboration to fight Tuberculosis

18-Feb-2008 - Intercell AG announced that a Tuberculosis vaccine, which is currently tested in clinical trials and which contains antigens discovered by Statens Serum Institut formulated with Intercells adjuvant IC31®, will be further developed in a partnership between SSI and Sanofi Pasteur. SSI and ...

Statens Serum Institut, Intercell, and Aeras announce the initiation of a clinical trial for a novel TB vaccine candidate

SSI's novel tuberculosis subunit vaccine HyVac4IC31 (AERAS404) enters phase I clinical trial in BCGvaccinated individuals

06-Dec-2007 - Statens Serum Institut (SSI), Intercell, and Aeras announced that SSI's novel prophylactic vaccine HyVac4IC31 (AERAS404) against TB have entered phase I clinical trials in BCGvaccinated individuals. The clinical trial has been initiated at the Karolinska Institute (Stockholm). The new TBvaccine ...

Crucell, AERAS and SATVI Announce Start of Tuberculosis Vaccine Clinical Trial in South Africa

15-May-2007 - Crucell N.V., the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative (SATVI) at the University of Cape Town announced the launch of a new Phase I clinical trial of the unique AdVac®-based tuberculosis vaccine, six months after launching a similar study in the ...

Aeras commits further USD$5 million to existing TB research agreement with Crucell

09-Mar-2007 - Crucell N.V. announced it will receive up to USD$5 million from Rockville, Maryland-headquartered Aeras Global TB Vaccine Foundation to support the advanced development of the candidate AdVac-based tuberculosis vaccine. "This technology, which is based on one of the most advanced vector delivery ...

Crucell and AERAS Announce Start of Tuberculosis Vaccine Clinical Trial

27-Oct-2006 - Crucell N.V. announced that it has started the phase I clinical trial of the AdVac®-based tuberculosis vaccine it is developing in partnership with The AERAS Global TB Vaccine Foundation. The clinical trial will be an open-label study that will test the vaccine in a dose-escalation trial ...

ACE Biosciences and Aeras Global TB Vaccine Foundation enter tubercolosis vaccine collaboration

22-Dec-2005 - ACE BioSciences A/S and the Aeras Global TB Vaccine Foundation of Bethesda, Maryland, US, have entered a collaboration whereby ACE BioSciences will support characterization of second-generation BCGbased tuberculosis (TB) vaccines under development by Aeras. The current TB vaccine, BCG, does not ...

Crucell and Aeras Announce Progress in TB Vaccine Program

12-Sep-2005 - Crucell N.V. and Aeras Global TB Vaccine Foundation announced the initiation of a series of clinical studies for their AdVac®-based TB vaccine. The studies, which follow promising results for the vaccine obtained in animal studies, are scheduled to start in Europe, the US and Africa in the second ...